Literature DB >> 11741787

Syntheses of fused heterocyclic compounds and their inhibitory activities for squalene synthase.

Takashi Miki1, Masakuni Kori, Akira Fujishima, Hiroshi Mabuchi, Ryu ichi Tozawa, Masahira Nakamura, Yasuo Sugiyama, Hidefumi Yukimasa.   

Abstract

A variety of fused heterocyclic compounds (2-11) were synthesized as a modification of the lead compound 1a and evaluated for their inhibition of squalene synthase. 4,1-Benzothiazepine derivative 2, 1,4-benzodiazepine derivative 6, 1,3-benzodiazepine derivative 7, 1-benzazepine derivative 9, and 4,1-benzoxazocine derivative 10 potently inhibited squalene synthase activity, whereas the 4,1-benzoxazepine derivatives 1 was the most potent inhibitor. 4,1-Benzothiazepine S-oxide derivative 4, 1,4-benzodiazepine derivative 5, 1,3,4-benzotriazepine derivative 8, and 1,2,3,4-tetrahydroquinoline derivative 11 were found to be weakly active. Comparison of the X-ray structures of these compounds (1a, 2, 4, 5, 7 and 10) suggests that orientation of the 5- (or 6)-phenyl group is important for activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11741787     DOI: 10.1016/s0968-0896(01)00289-9

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Do benzodiazepines mimic reverse-turn structures?

Authors:  Masayuki Hata; Garland R Marshall
Journal:  J Comput Aided Mol Des       Date:  2006-09-14       Impact factor: 3.686

2.  Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate.

Authors:  Ali Koohang; Jessica L Bailey; Robert M Coates; Hans K Erickson; David Owen; C Dale Poulter
Journal:  J Org Chem       Date:  2010-07-16       Impact factor: 4.354

3.  Production of benzazepine derivatives via four-component reaction of isatins: study of antioxidant activity.

Authors:  Fathali Gholami Orimi; Behrooz Mirza; Zinatossadat Hossaini
Journal:  Mol Divers       Date:  2020-06-10       Impact factor: 2.943

Review 4.  Human isoprenoid synthase enzymes as therapeutic targets.

Authors:  Jaeok Park; Alexios N Matralis; Albert M Berghuis; Youla S Tsantrizos
Journal:  Front Chem       Date:  2014-07-22       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.